GLP-1 pipeline: 2026 and beyond

A field guide to the next-generation GLP-1 / incretin / metabolic peptide programs likely to reshape the landscape over the next several years.

Why the next 24 months matter

The current GLP-1 era — semaglutide and tirzepatide as the dominant therapeutics — was largely set in 2017–2023. The next two years will see late-stage readouts that either consolidate that paradigm, expand it (broader indications, oral access), or partially replace it (monthly dosing, GIP-antagonist strategies, MASH-focused dual agonists).

The leading next-generation candidates

Retatrutide (Eli Lilly)
Triple GLP-1 / GIP / glucagon agonist; ~24% Phase 2 weight loss; TRIUMPH Phase 3 program in obesity, T2D, MASH, OSA, osteoarthritis, and CV outcomes.
MariTide (Amgen)
GLP-1 agonist + GIP receptor antagonist (antibody conjugate); ~21% Phase 2 weight loss on monthly dosing.
Survodutide (Boehringer / Zealand)
GLP-1 / glucagon dual agonist; Phase 2 ~19% weight loss; positive Phase 2 MASH readout; Phase 3 obesity and MASH (SYNCHRONIZE) underway.
Pemvidutide (Altimmune)
GLP-1 / glucagon dual with MASH focus; Phase 2 IMPACT and IMPROVE results favorable.
Mazdutide (Lilly / Innovent)
GLP-1 / glucagon dual; first dual incretin agonist approved for obesity in any major jurisdiction (China, 2025).
Orforglipron (Eli Lilly)
Oral non-peptide GLP-1; ACHIEVE T2D and ATTAIN obesity Phase 3; the leading candidate for once-daily oral GLP-1.
VK2735 (Viking Therapeutics)
GLP-1/GIP dual agonist; subcutaneous Phase 2 weight loss has been favorable; oral formulation under development.
CagriSema (Novo Nordisk)
Cagrilintide + semaglutide combination; REDEFINE Phase 3 program reignites the amylin angle alongside GLP-1.

What patterns are emerging

  1. Receptor stacking has limits. Going from single → dual → triple receptor activity has produced additive weight loss but also additive tolerability cost. Drugs that achieve large weight loss through clever receptor balance (MariTide's antagonism approach) or through alternative targeting (amylin in CagriSema) suggest the next frontier may not be more receptors but smarter use of existing ones.
  2. MASH and cardiometabolic indications are the next big indication expansion. Survodutide and pemvidutide are positioning specifically for liver disease.
  3. Oral access is shifting. Orforglipron's success or failure will reshape what "GLP-1 therapy" means at scale.
  4. Dosing intervals are extending. MariTide's monthly format previews a possible shift away from weekly dosing as the default.
  5. Muscle preservation strategies are becoming a development goal. Combination programs with anti-myostatin or anti-activin agents (e.g., bimagrumab + semaglutide) aim to preserve lean mass alongside fat loss.

What to read for

For practitioners and engaged readers, the most informative readouts in the next 12–24 months will be: TRIUMPH Phase 3 outcomes in obesity, T2D, MASH, and CV; ACHIEVE / ATTAIN final results for orforglipron; MariTide Phase 3; the first head-to-head comparisons among next-generation agents; and the maturing CV and renal outcomes programs (FLOW completed, additional cardiometabolic trials ongoing).

Bottom line

The GLP-1 class is not finished evolving. The 2026–2028 readouts will determine whether retatrutide displaces tirzepatide as the high-water-mark of injectable obesity therapy, whether oral non-peptide GLP-1s reach the market in earnest, and whether monthly antibody-conjugate strategies represent a credible alternative trajectory. The field is genuinely in motion.